Thrombin-activatable fibrinolysis inhibitor-a inhibitors: Drugs for sepsis or drugs for disseminated intravascular coagulation?

Critical Care Medicine

Volumn 37, Issue 5, 2009, Pages 1823-1824

  Dempfle, Carl Erik ^a   Borggrefe, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Disseminated intravascular coagulation; Sepsis; TAFIa; Thrombin

Indexed keywords

ANTIFIBRINOLYTIC AGENT; ANTITHROMBIN; D DIMER; FIBRIN; FIBRINOGEN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR A INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

BACTERIAL INFECTION; BLEEDING; CLINICAL FEATURE; DISSEMINATED INTRAVASCULAR CLOTTING; EDITORIAL; FIBRIN FORMATION; FIBRINOLYSIS; HUMAN; LABORATORY TEST; MICROVASCULATURE; MULTIPLE ORGAN FAILURE; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTHROMBIN TIME; SEPSIS;

ANIMALS; CARBOXYPEPTIDASE U; COHORT STUDIES; DISEASE MODELS, ANIMAL; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; RATS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEPSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 67650470173     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181a09708     Document Type: Editorial

References (28)

1. Muto Y, Suzuki K, Iida H, et al: EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats. Crit Care Med 2009; 37:1744-1749
2. Bajzar L, Manuel R, Nesheim ME: Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270:14477-14484
3. Wang W, Boffa MB, Bajzar L, et al: A study of the mechanism of inhibition of fibrino-lysis by activated thrombin-activable fibri-nolysis inhibitor. J Biol Chem 1998; 273: 27176-27181
4. Schneider M, Brufatto N, Neill E, et al: Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin. J Biol Chem 2004; 279:13340-13345
5. Bleyl U, Rossner JA: Globular hyaline microthrombi - Their nature and morphogenesis. Virchows Arch A Pathol Anat Histol 1976; 370: 113-128
6. Taylor FB Jr, Toh CH, Hoots WK, et al: Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86:1327-1330
7. Wada H, Gabazza EC, Asakura H, et al: Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): Diagnostic criteria of the International Society of Thrombosis and Hemostasis and of the Japanese Ministry of Health and Welfare for overt DIC. Am J Hematol 2003; 74:17-22
8. Gando S, Wada H, Asakura H, et al: Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients. Clin Appl Thromb Hemost 2005; 11:71-76
9. Dhainaut JF, Yan SB, Joyce DE, et al: Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004; 2:1924-1933
10. Bakhtiari K, Meijers JC, de Jonge E, et al: Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravas-cular coagulation. Crit Care Med 2004; 32: 2416-2421
11. Sivula M, Tallgren M, Pettila V: Modified score for disseminated intravascular coagulation in the critically ill. Intensive Care Med 2005; 31:1209-1214
12. Dempfle CE, Wurst M, Smolinski M, et al: Use of soluble fibrin antigen instead of D-dimer as fibrin-related marker may enhance the prognostic power of the ISTH overt DIC score. Thromb Haemost 2004; 91:812-818
13. Angstwurm MW, Dempfle CE, Spannagl M: New disseminated intravascular coagulation score: A useful tool to predict mortality in comparison with Acute Physiology and Chronic Health Evaluation II and Logistic Organ Dysfunction scores. Crit Care Med 2006; 34:314 -320; quiz 328
14. Alberio L, Lammle B, Esmon CT: Protein C replacement in severe meningococcemia: Rationale and clinical experience. Clin Infect Dis 2001; 32:1338-1346
15. Childers BJ, Cobanov B: Acute infectious purpura fulminans: A 15-year retrospective review of 28 consecutive cases. Am Surg 2003; 69:86-90
16. Muller FM, Ehrenthal W, Hafner G, et al: Purpura fulminans in severe congenital protein C deficiency: Monitoring of treatment with protein C concentrate. Eur J Pediatr 1996; 155:20-25
17. Watanabe R, Wada H, Watanabe Y, et al: Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 2001; 104:1-6
18. Asakura H, Ontachi Y, Mizutani T, et al: An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation. Crit Care Med 2001; 29:1164-1168
19. Geishofer G, Binder A, Muller M, et al: 4G/5G promoter polymorphism in the plasmino-gen-activator-inhibitor-1 gene in children with systemic meningococcaemia. Eur J Pediatr 2005; 164:486-490
20. Binder A, Endler G, Muller M, et al: 4G4G genotype of the plasminogen activator inhibitor-1 promoter polymorphism associates with disseminated intravascular coagulation in children with systemic meningococcemia. J Thromb Haemost 2007; 5:2049-2054
21. Paloma MJ, Paramo JA, Rocha E: Endotoxininduced intravascular coagulation in rabbits: Effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality. Thromb Haemost 1995; 74: 1578-1582
22. Montes R, Declerck PJ, Calvo A, et al: Prevention of renal fibrin deposition in endotox-in-induced DIC through inhibition of PAI-1. Thromb Haemost 2000; 84:65-70
23. Warren BL, Eid A, Singer P, et al: Caring for the critically ill patient. High-dose anti-thrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286:1869-1878
24. Kienast J, Juers M, Wiedermann CJ, et al: Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006; 4:90-97
25. Wada H, Mori Y, Okabayashi K, et al: High plasma fibrinogen level is associated with poor clinical outcome in DIC patients. Am J Hematol 2003; 72:1-7
26. Wiman B, Ranby M: Determination of soluble fibrin in plasma by a rapid and quantitative spectrophotometric assay. Thromb Haemost 1986; 55:189-193
27. Halvorsen S, Skjonsberg OH, Ruyter R, et al: Comparison of methods for detecting soluble fibrin in plasma. An in vitro study. Thromb Res 1990; 57:489-497
28. Bredbacka S, Blomback M, Wiman B: Soluble fibrin: A predictor for the development and outcome of multiple organ failure. Am J Hematol 1994; 46:289-294